Drug profile · INN
guselkumab
TREMFYA
guselkumab (TREMFYA) is a interleukin-23 inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — guselkumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 21
- Data quality
- 0.84
Quick answer
guselkumab (TREMFYA) is a interleukin-23 inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-23
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is guselkumab?
guselkumab (TREMFYA) is a interleukin-23 inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for guselkumab?
TREMFYA is a marketed brand name for guselkumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of guselkumab?
guselkumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.